Related Experiment Videos
Correction to: Response to the Letter to the Editor by Koneswarakantha and Ménard
Silke Janitza1, Madhurima Majumder2, Franco Mendolia3
1Bayer AG, Berlin, Germany.
Therapeutic Innovation & Regulatory Science
|March 21, 2022
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Interpretation of Change in Novel Digital Measures: A Statistical Review and Tutorial.
Digital biomarkers·2025
Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.
Orphanet journal of rare diseases·2022
elaborator: A Novel App for Insights into Laboratory Data of Clinical Trials.
Therapeutic innovation & regulatory science·2021
Analysis of IMPD Deficiencies in the Clinical Trial Approval Process.
Therapeutic innovation & regulatory science·2026
Lean-Agile Product Development in FDA Relevant and Regulated Medical Device Contexts.
Therapeutic innovation & regulatory science·2026
Regulatory Reliance in Latin America: Opportunities and Implementation Challenges for International Pharmaceutical Companies.
Therapeutic innovation & regulatory science·2026
Current Landscape of Investigator-Initiated Decentralized Clinical Trials in Japan: A Nationwide Survey.
Therapeutic innovation & regulatory science·2026
Beyond prediction: an evidenced-based framework for assessing site selection decisions.
Therapeutic innovation & regulatory science·2026
Contribution of Real-World Evidence for the Orphan Medicines Approvals in the European Union Between 2000 and 2025.
Therapeutic innovation & regulatory science·2026
Erratum.
Ocular oncology and pathology·2026
RETRACTION: Deep Realistic Facial Editing via Label-Restricted Mask Disentanglement.
Computational intelligence and neuroscience·2026
Corrigendum to: Prevalence and Determinants of the Pool Sign in Lung Cancer Patients with Brain Metastasis.
Current medical imaging·2026
Corrigendum to: FOLR1 Regulates the Malignant Progression of Glioblastoma through the SRC/ERK1/2 Axis.
Combinatorial chemistry & high throughput screening·2026